Research Paper Volume 13, Issue 21 pp 24136—24154
Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort
Figure 3. DDR mutations association with prognosis in 7 distinct cancers. (A–G) Association of DDR mutations with prognosis in 7 cancers in the MSKCC cohort; (H–N) Association of DDR mutations with prognosis in 7 cancers in the TCGA cohort. Cancer types that exhibited the survival benefits of NLRP3 mutations in the MSKCC and TCGA cohorts were respectively colored with green and blue.